BE678216A - - Google Patents

Info

Publication number
BE678216A
BE678216A BE678216DA BE678216A BE 678216 A BE678216 A BE 678216A BE 678216D A BE678216D A BE 678216DA BE 678216 A BE678216 A BE 678216A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BE678216A publication Critical patent/BE678216A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE678216D 1965-03-23 1966-03-22 BE678216A (Direct)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44220565A 1965-03-23 1965-03-23
US57654966A 1966-09-01 1966-09-01
US734770A 1970-01-28 1970-01-28

Publications (1)

Publication Number Publication Date
BE678216A true BE678216A (Direct) 1966-09-22

Family

ID=27358345

Family Applications (1)

Application Number Title Priority Date Filing Date
BE678216D BE678216A (Direct) 1965-03-23 1966-03-22

Country Status (5)

Country Link
US (1) US3609152A (Direct)
BE (1) BE678216A (Direct)
DE (1) DE1620127C3 (Direct)
FR (1) FR5267M (Direct)
GB (3) GB1062357A (Direct)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2198751A1 (Direct) * 1972-09-09 1974-04-05 Pfizer

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
US4625026A (en) * 1982-12-30 1986-11-25 Biomeasure, Inc. 2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections
US4814335A (en) * 1982-12-30 1989-03-21 Biomeasure, Incorporated Antiviral compounds
JPS6442472A (en) * 1987-08-10 1989-02-14 Kanebo Ltd Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient
US4877790A (en) * 1987-12-15 1989-10-31 Kanebo Limited Quinazoline derivative, processes for its production, and cerebral dysfunction remedying agent comprising it as active ingredient
TW334434B (en) * 1995-05-16 1998-06-21 Kanebo Ltd Novel quinazoline compound and anti-tumor agent
WO1997042192A1 (de) * 1996-05-07 1997-11-13 Basf Aktiengesellschaft Imidazo-chinazoline, sie enthaltende mittel und deren verwendung zur bekämpfung von schadpilzen und tierischen schädlingen
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
CN1237060C (zh) * 2001-01-02 2006-01-18 弗·哈夫曼-拉罗切有限公司 用作α1A/B肾上腺素能受体拮抗剂的喹唑酮衍生物
CN1209392C (zh) * 2001-05-14 2005-07-06 阿姆诺洼化学有限公司 由含侧氟碳基的环状单体得到的聚合物表面活性剂
EP1398032A1 (en) * 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
EP1407774A1 (en) * 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
DK1557414T3 (da) 2002-10-01 2012-05-29 Mitsubishi Tanabe Pharma Corp IsoquinoIin-forbindelser og medicinsk anvendelse deraf
CA2507027C (en) 2002-11-22 2012-05-08 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
EA009875B1 (ru) 2003-11-20 2008-04-28 Янссен Фармацевтика Н.В. 6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
UA91002C2 (ru) 2003-11-20 2010-06-25 Янссен Фармацевтика Н.В. 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы
MXPA06014541A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de quinazolindiona como inhibidores de la poli(adp-ribosa) polimerasa.
JP4836946B2 (ja) 2004-06-30 2011-12-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としての置換２−アルキルキナゾリノン誘導体
US7803795B2 (en) 2004-06-30 2010-09-28 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
CA2598301C (en) * 2005-02-18 2013-05-28 Mitsubishi Pharma Corporation Salt of proline derivative, solvate thereof, and production method thereof
MX2008012655A (es) 2006-03-31 2008-12-16 Janssen Pharmaceutica Nv Benzoimidazol-2-il-pirimidinas y -pirazinas como moduladores de receptor de histamina h4.
SI2134691T1 (sl) 2007-03-08 2012-06-29 Janssen Pharmaceutica Nv Derivati kvinolina kot PARP in TANK inhibitorji
JP5525447B2 (ja) 2007-10-26 2014-06-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキノリノン誘導体
JP5464609B2 (ja) 2008-03-27 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チューブリン重合阻害剤としてのキナゾリノン誘導体
DK2271626T3 (en) 2008-03-27 2015-02-23 Janssen Pharmaceutica Nv TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN
NZ599747A (en) * 2008-06-30 2013-03-28 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EP2376495A4 (en) 2008-12-08 2012-10-31 Vm Pharma Llc COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
EP2526099B1 (en) * 2010-01-18 2016-03-30 MSN Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
US9708300B2 (en) * 2011-03-20 2017-07-18 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
DE102011113749A1 (de) * 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
MX342140B (es) * 2011-09-30 2016-09-14 Janssen Pharmaceutica Nv Sal clorhidrato cristalina de (1-(4-fluorofenil)-1h-indol-5-il)-(3 -(4-(tiazol-2-carbonil)piperazin-1-il) azetidin-1-il)metanona y su uso en el tratamiento del dolor y transtornos metabolicos.
SG10201700804XA (en) * 2012-03-15 2017-03-30 Celgene Avilomics Res Inc Solid forms of an epidermal growth factor receptor kinase inhibitor
EP2825042B1 (en) 2012-03-15 2018-08-01 Celgene CAR LLC Salts of an epidermal growth factor receptor kinase inhibitor
US20130261134A1 (en) * 2012-03-30 2013-10-03 Boehringer Ingelheim International Gmbh Mesylate salt forms of a potent hcv inhibitor
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US8859575B2 (en) 2013-03-06 2014-10-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
US8999992B2 (en) * 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
CA2932560C (en) * 2013-12-03 2022-11-15 Amgen Inc. Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine pharmaceutically acceptable salts and uses thereof
TW201613892A (en) 2014-08-13 2016-04-16 Celgene Avilomics Res Inc Forms and compositions of an ERK inhibitor
AU2015318324A1 (en) 2014-09-17 2017-04-06 Mundipharma International Corporation Limited Crystalline forms of tyrosine kinase inhibitors and their salts
US10759782B2 (en) * 2016-03-22 2020-09-01 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274194A (en) * 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
US3301855A (en) * 1963-04-22 1967-01-31 Ciba Geigy Corp Derivatives of 4-nu-(2-nu, nu-dimethylaminolower alkyl)-amino quinazoline
DE1249281B (Direct) * 1963-05-18
US3257400A (en) * 1964-06-10 1966-06-21 Searle & Co 2-amino-5, 6-dihydrobenzo[h]quinazolin-4(3h)-one and congeners

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2198751A1 (Direct) * 1972-09-09 1974-04-05 Pfizer

Also Published As

Publication number Publication date
DE1620127B2 (de) 1974-01-17
GB1062357A (en) 1967-03-22
US3609152A (en) 1971-09-28
DE1620127A1 (de) 1970-03-12
GB1174273A (en) 1969-12-17
FR5267M (Direct) 1967-07-31
DE1620127C3 (de) 1974-10-10
GB1174272A (en) 1969-12-17

Similar Documents

Publication Publication Date Title
AU6521365A (Direct)
BE674176A (Direct)
BE674501A (Direct)
BE658163A (Direct)
BE659563A (Direct)
BE659905A (Direct)
BE660633A (Direct)
BE662523A (Direct)
BE663638A (Direct)
BE666367A (Direct)
BE668724A (Direct)
BE669403A (Direct)
BE669422A (Direct)
BE669740A (Direct)
BE669921A (Direct)
BE671031A (Direct)
BE671218A (Direct)
BE671542A (Direct)
BE672013A (Direct)
BE672185A (Direct)
BE675122A (Direct)
BE674025A (Direct)
BE674154A (Direct)
BE675187A (Direct)
BE674177A (Direct)